Abeona Therapeutics (NQ: ABEO )
1.240 USD UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2021 Add to My Watchlist
Press releases about Abeona Therapeutics
Abeona Therapeutics to Present at Upcoming Investor Conferences
September 07, 2021
Thinking about buying stock in electroCore, General Electric, Gaotu Techedu, New Oriental Education, or Abeona Therapeutics?
July 28, 2021
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
July 28, 2021
Thinking about buying stock in Xenetic Biosciences, Abeona Therapeutics, IMV Inc, Marathon Digital, or Riot Blockchain?
July 26, 2021
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
July 26, 2021
New data from Phase 1/2 Transpher A study presented at 16th International Symposium on MPS and Related Diseases
Thinking about buying stock in Veoneer, Abeona Therapeutics, ConforMIS, Neurobo Pharmaceuticals, or Acutus Medical?
July 23, 2021
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis Bullosa
July 23, 2021
Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting
July 07, 2021
Thinking about buying stock in La Jolla Pharmaceutical, The GEO Group, Abeona Therapeutics, Sellas Life Sciences, or Naked Brand?
June 03, 2021
Thinking about buying stock in GameStop, AMC Entertainment, Meredith Corp, Sundial Growers, or Abeona Therapeutics?
May 03, 2021
Thinking about buying stock in Motus GI, Abeona Therapeutics, Skillz Inc, Marker Therapeutics, or Nikola Corp?
April 23, 2021
Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Starg
April 20, 2021
Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
April 19, 2021
New board members add a wealth of experience in clinical development and manufacturing of cell therapy and gene therapy products
Abeona Therapeutics Inc. (NASDAQ:ABEO) Investor Alert: Investigation over Potential Wrongdoing
April 08, 2021
San Diego, CA -- (SBWIRE) -- 04/08/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Abeona Therapeutics Inc.
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
March 25, 2021
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
March 23, 2021
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
March 22, 2021
CEO appointment provides continuity and reflects company’s demonstrated strong operational performance
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 22, 2021
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene
February 12, 2021
Thinking about buying stock in Heat Biologics, Zosano Pharma, Glu Mobile, AzurRx BioPharma, or Abeona Therapeutics?
February 09, 2021
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
February 02, 2021
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
January 25, 2021
Clinical trial amendment successfully completed for co-primary endpoints of partial wound closure and mean pain reduction